GB201701400D0 - Compound for use in medicine - Google Patents
Compound for use in medicineInfo
- Publication number
- GB201701400D0 GB201701400D0 GBGB1701400.2A GB201701400A GB201701400D0 GB 201701400 D0 GB201701400 D0 GB 201701400D0 GB 201701400 A GB201701400 A GB 201701400A GB 201701400 D0 GB201701400 D0 GB 201701400D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- medicine
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1701400.2A GB2559162A (en) | 2017-01-27 | 2017-01-27 | Compound for use in medicine |
| PCT/GB2018/050222 WO2018138510A1 (en) | 2017-01-27 | 2018-01-26 | Mebendazole for use in the treatment of cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1701400.2A GB2559162A (en) | 2017-01-27 | 2017-01-27 | Compound for use in medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB201701400D0 true GB201701400D0 (en) | 2017-03-15 |
| GB2559162A GB2559162A (en) | 2018-08-01 |
Family
ID=58462631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB1701400.2A Withdrawn GB2559162A (en) | 2017-01-27 | 2017-01-27 | Compound for use in medicine |
Country Status (2)
| Country | Link |
|---|---|
| GB (1) | GB2559162A (en) |
| WO (1) | WO2018138510A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115721722A (en) * | 2022-11-09 | 2023-03-03 | 浙江大学 | Pharmaceutical composition for treating EGFR-TKI-resistant non-small cell lung cancer |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110585199A (en) * | 2019-08-16 | 2019-12-20 | 华东理工大学 | Application of mebendazole in preparation of medicine for treating acute T-lymphoblastic leukemia |
| CA3097717A1 (en) * | 2020-11-02 | 2022-05-02 | Skymount Medical Us Inc. | TYROSINE KINASE IN THE TREATMENT OF CORONAVIRUS DISEASES |
| CN115177590A (en) * | 2022-04-20 | 2022-10-14 | 南昌大学抚州医学院 | Preparation method and application of mebendazole liposome |
| EP4537834A1 (en) * | 2023-10-11 | 2025-04-16 | Eberhard Karls Universität Tübingen (Medizinische Fakultät) | Precision immunosuppression as prevention and therapy for graft-versus-host disease |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050038022A1 (en) * | 2001-03-26 | 2005-02-17 | Unisearch Limited | Method for treatment of cancer and compositions for use therein |
| EP2156834A1 (en) * | 2008-08-08 | 2010-02-24 | S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. | Ophthalmic pharmaceutical compositions comprising Sorafenib for the treatment of neoangiogenic pathologies of the eye |
| US20150065526A1 (en) * | 2013-09-05 | 2015-03-05 | Emory University | Overcoming acquired resistance to chemotherapy treatments through suppression of stat3 |
| JP2017031059A (en) * | 2014-01-29 | 2017-02-09 | 学校法人慶應義塾 | Cancer stem cell growth inhibitor and intracellular active oxygen accumulation inducer |
| US11110079B2 (en) * | 2015-02-06 | 2021-09-07 | The Johns Hopkins University | Mebendazole polymorph for treatment and prevention of tumors |
-
2017
- 2017-01-27 GB GB1701400.2A patent/GB2559162A/en not_active Withdrawn
-
2018
- 2018-01-26 WO PCT/GB2018/050222 patent/WO2018138510A1/en not_active Ceased
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115721722A (en) * | 2022-11-09 | 2023-03-03 | 浙江大学 | Pharmaceutical composition for treating EGFR-TKI-resistant non-small cell lung cancer |
| CN115721722B (en) * | 2022-11-09 | 2024-01-05 | 浙江大学 | Pharmaceutical composition for treating EGFR-TKI resistant non-small cell lung cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018138510A1 (en) | 2018-08-02 |
| GB2559162A (en) | 2018-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL252532A0 (en) | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | |
| IL254552A0 (en) | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | |
| IL247072A0 (en) | Medical use | |
| IL283335B (en) | Dihydropyrimidin-2-one compounds and medical use thereof | |
| GB201502412D0 (en) | Therapeutic use | |
| ZA201801134B (en) | Hydroxytriazine compound and medical use thereof | |
| GB201701400D0 (en) | Compound for use in medicine | |
| ZA201701492B (en) | Pyrazolothiazole compound and medicine | |
| GB201517133D0 (en) | New pharmaceutical use | |
| SG11201608123VA (en) | Pharmaceutical composition for external use | |
| GB201506786D0 (en) | Therapeutic use | |
| GB201616880D0 (en) | Compound for use in medicine | |
| SG11201608124XA (en) | Pharmaceutical composition for external use | |
| GB201701388D0 (en) | Compound for use in medicine | |
| GB201715316D0 (en) | Medicine Etc | |
| GB201702051D0 (en) | New Pharmaceutical use | |
| GB201616767D0 (en) | New pharmaceutical use | |
| GB201601991D0 (en) | Medicine | |
| SG11201608122PA (en) | Pharmaceutical composition for external use | |
| GB201517454D0 (en) | New pharmaceutical use | |
| GB201517132D0 (en) | New pharmaceutical use | |
| GB201508611D0 (en) | New pharmaceutical use | |
| GB201508613D0 (en) | New pharmaceutical use | |
| GB201507813D0 (en) | New pharmaceutical use | |
| PH32015000070S1 (en) | Medical container |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |